MUC1-Derived Peptide HLA-A Binding for Cancer Immunotherapy

Solution Overview

Problem

There is a need for additional immunogenic peptides that can bind to multiple types of human leukocyte antigens (HLA) to effectively treat or prevent various cancers, as existing peptides are limited in their applicability across different HLA types.

Innovation Solution

A peptide with an amino acid sequence derived from MUC1, specifically Sequence ID Nos. 1 or 3, which exhibits a high binding affinity to one or more types of HLA-A molecules, thereby inducing a strong immune response against cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If existing peptides are used for cancer treatment, then some HLA-binding capability is achieved, but the applicability across different HLA types is limited

Engineering Contradiction:

Improveapplicability across different HLA typesVSAvoidHLA-binding capability

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The peptide is designed to bind to multiple HLA-A molecule types simultaneously, making it universally applicable across different HLA types. The amino acid sequence is specifically engineered to interact with conserved regions of HLA-A molecules, enabling broad compatibility while maintaining reliable binding capability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The peptide structure is optimized by adjusting amino acid composition and sequence to achieve optimal binding affinity across multiple HLA-A types. Specific amino acid residues are selected to match the binding groove characteristics of different HLA-A molecules, thereby improving both versatility and reliability through parameter optimization.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If multi-type immunogenic peptides are developed, then broader HLA coverage is achieved, but the complexity of identification and validation increases

Engineering Contradiction:

ImproveHLA-binding capabilityVSAvoididentification and validation complexity

Core Design Contradiction:

Adaptability or versatilityVSDifficulty of detecting and measuring

Solution Approach 1:

The peptide is designed to bind to multiple HLA-A molecule types simultaneously, making it universally applicable across different HLA types. The amino acid sequence is specifically engineered to interact with conserved regions of HLA-A molecules, enabling broad compatibility while maintaining reliable binding capability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The peptide structure is optimized by adjusting amino acid composition and sequence to achieve optimal binding affinity across multiple HLA-A types. Specific amino acid residues are selected to match the binding groove characteristics of different HLA-A molecules, thereby improving both versatility and reliability through parameter optimization.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide demonstrates a high ability to induce cytotoxic T cells (CTLs) and has a broad HLA-binding capability, making it suitable for use in cancer vaccines and dendritic cell therapies, potentially covering a wide range of cancer patients.

Implementation Method 1

The peptide of the present invention has a high HLA-binding property and a high ability to induce CTLs

Methodology Applied

Scientific EffectAntigen presentation:

Implementation Method 2

a peptide consisting of an amino acid sequence of either Sequence ID No. 1 or 3, wherein the peptide can bind to one or more types of HLA-A molecules

Methodology Applied

Scientific EffectHLA binding:

Data Source

PatentEP3269726B1Peptide derived from MUC1, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cells

Publication Date: 2025.05.07 NEC CORP

Figure 1~2
Figure 3~4

AI summary

The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.